News
Researchers share that perfluorohexylactane eye drops offer rapid relief for dry eye disease, enhancing patient comfort ...
A study reveals attrition rates in geographic atrophy patients on complement inhibitor therapies, highlighting the need for ...
OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform ...
VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the ...
Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and ...
Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, ...
IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term ...
SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term ...
Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings ...
Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results